Table 2.

Studies investigating androgen receptor (AR) inhibitors in TNBC.

Phase	Clinical Trial	Treatment	ClinicalTrials.gov Identifier
Phase 1/2	CYP17 Lyase and Androgen Receptor Inhibitor treatment with Seviteronel	Seviteronel	NCT02580448
Phase 1 Phase 2	A phase I/II, single arm, non-randomized study of Ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with Bicalutamide, an androgen receptor (AR) inhibitor	Ribociclib Bicalutamide	NCT03090165
Phase 1 Phase 2	A phase Ib/II trial of Taselisib (GDC-0032), a PI3K inhibitor, in combination with Enzalutamide in patient with AR+veTNBC	Enzalutamide Taselisib	NCT02457910
Phase 2	A phase 2 open-label study to evaluate the efficacy and safety of VT-464, previous treatment with Enzalutamide	VT-464	NCT02130700